Budde, L. E., Kamdar, M., Assouline, S. E., Chavez, J. C., Ghosh, N., Ollila, T. A., Hodson, D. J., Modi, D., Bastos-Oreiro, M., Naik, S. G., Nakhoda, S. K., Batlevi, C. L., Wang, J., Makadia, S., Kwan, A., Penuel, E., Jing, J., Wu, H., Ead, W., Pham, S., To, I., Wei, M. C., Wang, M. L. (2026). Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. https://doi.org/10.1182/blood.2025032422